Expert Interview
A Third Look: Discussing the potential of AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab) for patients with moderate to very severe COPD and the results from the Phase IIa COURSE trial presented in May at ATS conference.
Ticker(s): AMGN, AZNDr. Michael Burk
- Board certified pulmonary and critical care physician in a hospital, ICU, and pulmonary clinic setting
- Clinical expertise includes point of care ultrasound evaluation (POCUS), a wide variety of pulmonary diseases including COPD, interstitial lung disease, post-COVID lung disease, asthma, lung cancer, and other respiratory conditions.
- Trained in advanced bronchoscopy procedures including endobronchial ultrasound (EBUS) guided biopsy and robotic bronchoscopy.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
